FDA Review of Lilly’s Experimental Cancer Treatment shows Clot Risk amid Encouraging Results
7/8/2015 The U.S. Food and Drug Administration (FDA) released the results of a 1093-patient study on Tuesday of drugmaker, Eli Lilly’s experimental drug necitumumab, aimed at treating a certain form of lung cancer. The information comes as the FDA will be conducting a panel of outside experts on Thursday, July 9th that will review the